Drugs / BR1733
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05749549 | Apr 2023 → May 2025 overdue | cancer of unknown primary site, diffuse large B-cell lymphoma, follicular lymphoma, peripheral T-cell lymphoma, not otherwise specified | Shanghai Blueray Biopharma Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BR1733 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05749549 ↗ |
| Route | Oral | “oral administration of BR1733” NCT05749549 ↗ |